GDF11 : An emerging therapeutic target for liver diseases and fibrosis
© 2024 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd..
Growth differentiation factor 11 (GDF11), also known as bone morphogenetic protein 11 (BMP11), has been identified as a key player in various biological processes, including embryonic development, aging, metabolic disorders and cancers. GDF11 has also emerged as a critical component in liver development, injury and fibrosis. However, the effects of GDF11 on liver physiology and pathology have been a subject of debate among researchers due to conflicting reported outcomes. While some studies suggest that GDF11 has anti-aging properties, others have documented its senescence-inducing effects. Similarly, while GDF11 has been implicated in exacerbating liver injury, it has also been shown to have the potential to reduce liver fibrosis. In this narrative review, we present a comprehensive report of recent evidence elucidating the diverse roles of GDF11 in liver development, hepatic injury, regeneration and associated diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver fibrosis and hepatocellular carcinoma. We also explore the therapeutic potential of GDF11 in managing various liver pathologies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Journal of cellular and molecular medicine - 28(2024), 7 vom: 31. März, Seite e18140 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Habibi, Pardis [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bone Morphogenetic Proteins |
|---|
| Anmerkungen: |
Date Completed 19.03.2024 Date Revised 20.03.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1111/jcmm.18140 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369845404 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369845404 | ||
| 003 | DE-627 | ||
| 005 | 20240320234759.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240318s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/jcmm.18140 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1337.xml |
| 035 | |a (DE-627)NLM369845404 | ||
| 035 | |a (NLM)38494851 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Habibi, Pardis |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a GDF11 |b An emerging therapeutic target for liver diseases and fibrosis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.03.2024 | ||
| 500 | |a Date Revised 20.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd. | ||
| 520 | |a Growth differentiation factor 11 (GDF11), also known as bone morphogenetic protein 11 (BMP11), has been identified as a key player in various biological processes, including embryonic development, aging, metabolic disorders and cancers. GDF11 has also emerged as a critical component in liver development, injury and fibrosis. However, the effects of GDF11 on liver physiology and pathology have been a subject of debate among researchers due to conflicting reported outcomes. While some studies suggest that GDF11 has anti-aging properties, others have documented its senescence-inducing effects. Similarly, while GDF11 has been implicated in exacerbating liver injury, it has also been shown to have the potential to reduce liver fibrosis. In this narrative review, we present a comprehensive report of recent evidence elucidating the diverse roles of GDF11 in liver development, hepatic injury, regeneration and associated diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver fibrosis and hepatocellular carcinoma. We also explore the therapeutic potential of GDF11 in managing various liver pathologies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a GDF11 | |
| 650 | 4 | |a HCC | |
| 650 | 4 | |a MAFLD | |
| 650 | 4 | |a NAFLD | |
| 650 | 4 | |a growth differentiation factor 11 | |
| 650 | 7 | |a Growth Differentiation Factors |2 NLM | |
| 650 | 7 | |a Bone Morphogenetic Proteins |2 NLM | |
| 650 | 7 | |a GDF11 protein, human |2 NLM | |
| 700 | 1 | |a Falamarzi, Kimia |e verfasserin |4 aut | |
| 700 | 1 | |a Ebrahimi, Niloofar Dehdari |e verfasserin |4 aut | |
| 700 | 1 | |a Zarei, Mohammad |e verfasserin |4 aut | |
| 700 | 1 | |a Malekpour, Mahdi |e verfasserin |4 aut | |
| 700 | 1 | |a Azarpira, Negar |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of cellular and molecular medicine |d 2000 |g 28(2024), 7 vom: 31. März, Seite e18140 |w (DE-627)NLM118801236 |x 1582-4934 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2024 |g number:7 |g day:31 |g month:03 |g pages:e18140 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/jcmm.18140 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2024 |e 7 |b 31 |c 03 |h e18140 | ||